CTRI/2020/07/026530尚未招募2 期
A multi-centric, open labelled, double-arm, phase II/III interventional study to evaluate the efficacy of composite Ayurvedic formulations for treatment of COVID-19 infections
SASTRA Deemed University0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •i.Males and females between 18 and 70 years of age will be informed of the nature of the study and informed written consent will be obtained
- •ii.COVID positive patients in the hospitals and home quarantine patients
- •iii.Laboratory confirmed COVID 19 with or without symptoms but NOT with active illness (ventilator support)
- •iv.Body weights within 25% of the appropriate weight range
- •v.Twelve lead ECG without significant abnormalities
排除标准
- •i.Persons already treated with any of the study drugs during the last 30 days
- •ii.Pregnant and lactating females and those who have a pregnancy plan
- •iii.Known allergy to any of the medications used in this trial
- •iv.Any disease or condition, which might compromise the haematopoietic, renal, liver, pulmonary, central nervous, cardiovascular, immunological, dermatological, gastrointestinal system
- •v.History of allergic conditions â?? asthma, urticaria, eczema
- •vi.History of autoimmune disorders â?? lupus erythematosis (SLE)
- •vii.History of alcohol addiction
- •viii.History or presence of dyspepsia, gastric ulcer or duodenal ulcer
- •ix.History of psychiatric disorders
- •x.Presence of clinically significant abnormal laboratory results during screening. Use of any recreational drugs or a history of drug addiction
- •xi.Subjects with HIV, HBV and HCV
研究者
相似试验
招募中
Unknown
A multicenter study to evaluate the safety and efficacy of T-DXd in combination with ramucirumab in patients with HER2 low mutations gastric or gastroesophageal junction (GEJ) adenocarcinomaKCT0008627Yonsei University Health System, Severance Hospital58
进行中（未招募）
1 期
Phase II study of the combination of Pembrolizumab and Lenvatinib, in pre-treated thymic CArcinoma paTIents (PECATI).Metastatic Thymic Carcinoma & B3-thymoma.MedDRA version: 21.1Level: PTClassification code 10055108Term: Thymic cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10043670Term: ThymomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-000397-18-FRMedica Scientia Innovation Research S.L (MEDSIR)43
进行中（未招募）
1 期
Phase II study of the combination of Pembrolizumab and Lenvatinib, in pre-treated thymic CArcinoma paTIents (PECATI).Metastatic Thymic Carcinoma & B3-thymomaMedDRA version: 20.0Level: PTClassification code 10043670Term: ThymomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10055108Term: Thymic cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-000397-18-ITMEDICA SCIENTIA INNOVATION RESEARCH S.L.43
进行中（未招募）
1 期
A Multicentric, Open-Label, Single Arm Phase II Study To Evaluate The Efficacy AndSafety Of The Combination Of PEmbrolizumab And Lenvatinib In Pre-Treated Thymic CArcinomaPaTIents. PECATI”.Metastatic Thymic Carcinoma & B3-thymoma.CTIS2023-508001-25-00Medica Scientia Innovation Research S.L.43
进行中（未招募）
1 期
A Phase Ib/II, Multicenter, Single Arm, Open-Label Study, To Evaluate the Safety, Tolerability and Efficacy of the BL-8040 and Atezolizumab Combination for Maintenance Treatment in Subjects with Acute Myeloid Leukemia who are 60 Years or Older - The BATTLE StudyAcute Myeloid LeukemiaEUCTR2017-002237-29-SKBioLineRx, Ltd.60